Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8625286 | 0.85 | CYP2A6 (0.48) | CYP19A1CNR1SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL3374829 | 0.84 | SLC6A2 (0.51) | CYP19A1CNR1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL13113802 | 0.82 | SLC6A2 (0.53) | CYP19A1CNR1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3374924 | 0.82 | SLC6A2 (0.56) | CNR1SLC6A2SLC6A3SLC6A4CNR2 | |
| SCHEMBL27614823 | 0.82 | SLC6A2 (0.56) | CNR1SLC6A2SLC6A3SLC6A4CNR2 | |
| SCHEMBL3374922 | 0.82 | SLC6A2 (0.56) | CNR1SLC6A2SLC6A3SLC6A4CNR2 | |
| SCHEMBL13113844 | 0.81 | SLC6A2 (0.49) | CYP19A1CNR1SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3374963 | 0.81 | SLC6A2 (0.51) | CYP19A1CNR1SLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3371830 | 0.80 | SLC6A2 (0.55) | CNR1SLC6A2SLC6A3SLC6A4CNR2 | |
| Hydrochloric Acid SCHEMBL3371068 | 0.80 | SLC6A2 (0.55) | CNR1SLC6A2SLC6A3SLC6A4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-1496838-B1 | SUBSTITUTED AMIDES | MERCK SHARP & DOHME (US) | 2010-11-03 | — | — | EP | disclosed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816534-B2 | Substituted amides | MERCK SHARP & DOHME CORP. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7667053-B2 | Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders | MERCK & CO., INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090258884-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258884-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-6972295-B2 | Substituted amides | MERCK & CO., INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20050239828-A1 | Spirocyclic amides as cannabinoid receptor modulators | MERCK & CO., INC. (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050234061-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2005-10-20 | — | — | US | disclosed |
| US-20050203112-A1 | Bicyclic amides | MERCK SHARP & DOHME CORP. | 2005-09-15 | — | — | US | disclosed |
| US-20050154202-A1 | Substituted aryl amides | MERCK & CO., INC. | 2005-07-14 | — | — | US | disclosed |
| CN-1639112-A | Substituted amides having cannabinoid-1 receptor activity | MERCK & CO INC (US) | 2005-07-13 | — | — | CN | disclosed |
| WO-2005044785-A1 | ARALKYL AMINES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| EP-1499306-A2 | BICYCLIC AMIDES | Merck & Co., Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | MERCK SHARP & DOHME LLC | 2004-03-25 | — | — | US | disclosed |
| WO-2003086288-A2 | BICYCLIC AMIDES | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154202-A1 | Substituted aryl amides | CNR1, CNR2, FAAH | CYP19A1 1009/4885CNR1 1/4885SLC6A2 1641/4885 |
| US-20050203112-A1 | Bicyclic amides | CNR1, CNR2, FAAH | CYP19A1 1296/4885CNR1 1/4885SLC6A2 1786/4885 |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | CNR1, CNR2, MAG | CYP19A1 2011/4885CNR1 1/4885SLC6A2 1371/4885 |
| US-20050239828-A1 | Spirocyclic amides as cannabinoid receptor modulators | CNR1, CNR2, MAG | CYP19A1 1414/4885CNR1 1/4885SLC6A2 2117/4885 |
| US-20090258884-A1 | Substituted amides | CNR1, CNR2, FAAH | CYP19A1 1207/4885CNR1 1/4885SLC6A2 1525/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | CYP19A1 1290/4885CNR1 1/4885SLC6A2 1390/4885 |
| US-20050234061-A1 | Substituted amides | CNR1, CNR2, FAAH | CYP19A1 1207/4885CNR1 1/4885SLC6A2 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.